Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1

Conditions

Multiple Myeloma 229Lymphoma 30Hematologic Neoplasms 21Recurrence 17Neoplasms 14Neoplasms, Plasma Cell 13Immunoglobulin Light-chain Amyloidosis 13Lymphoma, Non-Hodgkin 12Leukemia, Lymphocytic, Chronic, B-Cell 12Leukemia, Myeloid, Acute 10Lymphoma, Mantle-Cell 9Smoldering Multiple Myeloma 8Prostatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Myelodysplastic Syndromes 8Lymphoma, Large B-Cell, Diffuse 8Hodgkin Disease 8Ovarian Neoplasms 6Lung Neoplasms 6Leukemia, Plasma Cell 6Breast Neoplasms 6Waldenstrom Macroglobulinemia 5Melanoma 5Lymphoma, Follicular 5Monoclonal Gammopathy of Undetermined Significance 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4

Interventions

selinexor 1pazopanib 1Proton Therapy 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myoepithelioma × Plasma cell × 30 days × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡